JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month
September 3, 2019 9:00 AM EDTSocial media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today To further support the MPN community, for every weekly challenge completed in September, Incyte will donate to The Leukemia & Lymphoma Society
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (NASDAQ: INCY) is proud to further elevate awareness of myeloproliferative neoplasms (MPNs) throughout the month of September in honor of Blood Cancer Awareness Month and... More
Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
September 3, 2019 8:14 AM EDTUpdated Phase 2 results from the FIGHT-202 study highlight the potential of pemigatinib as a treatment option for patients with previously treated, advanced cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and... More
